Key Segments:
By Cell Type
-
T Cells
-
NK Cells
-
Macrophages
-
Others
By Product
-
Consumables
-
Instruments
-
Software & Services
By Disease Indication
-
Cancer
-
Autoimmune Diseases
-
Infectious Diseases
-
Others
By End Use
-
Pharmaceutical and Biotechnology Companies
-
Academic and Research Institutes
-
Contract Research Organizations
-
Hospitals and Clinics
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Poland
-
Russia
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization:
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
The market includes Thermo Fisher Scientific, Danaher, Merck KGaA, Lonza, Sartorius, Miltenyi Biotec, Terumo Blood and Cell Technologies, Takara Bio, Bio-Techne, Agilent Technologies, Bio-Rad Laboratories, STEMCELL Technologies, MaxCyte, Catalent, Charles River Laboratories, AGC Biologics and Oxford Biomedica, among others. These companies compete on reagent breadth, manufacturing platform capability, contract manufacturing capacity and global distribution reach.
The main opportunities lie in extending automated, accessible manufacturing technology into emerging markets, and supporting the expansion of engineered cell therapy development beyond oncology into autoimmune disease and other new indications.
The key growth factor is rising demand for the reagents and manufacturing platforms underpinning engineered cell therapy development, reinforced by strong commercial sales growth from approved CAR-T therapies that encourages continued investment across new cell types and indications.
By cell type, the T Cells segment dominated the market with approximately 41.00% share in 2025, supported by its established manufacturing processes and the clinical precedent of every currently approved CAR-T therapy.
North America dominated the market with approximately 40.50% share in 2025, supported by its dense concentration of pharmaceutical developers and academic cancer centers. Asia Pacific is the fastest-growing region with a projected CAGR of 22.80% from 2026 to 2035.
North America dominated the market with approximately 40.50% share in 2025, supported by its dense concentration of pharmaceutical developers and academic cancer centers. Asia Pacific is the fastest-growing region with a projected CAGR of 22.80% from 2026 to 2035.
